US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Report from Annual general meeting of XVIVO Perfusion AB (publ)

The following resolutions were amongst those adopted at XVIVO Perfusion’s Annual General Meeting held on March 31, 2020: • No dividend will be paid for the financial year 2019. • Gösta Johannesson, Camilla Öberg, Folke Nilsson, Yvonne Mårtensson and Dag Andersson were re-elected as members of the Board and Gösta Johannesson was elected Chairman of the Board, all in accordance with the proposal of the Election Committee. KPMG was elected as the company's auditor with Jan Malm as principal auditor until the end of the AGM for the financial year 2020. • Board remuneration were

XVIVO Perfusion AB (publ) issue of warrants of series 2019/2021 fully subscribed

The annual general meeting in XVIVO Perfusion AB (publ) (”XVIVO”) on 25 April 2019 resolved to issue up to 351,000 share warrants of series 2019/2021 to employees of XVIVO and XVIVO’s Swedish subsidiaries, with a date of employment on or before 18 October 2019. A total of 351 000 warrants were subscribed which means that the issue has been subscribed in full.Each warrant entitles to subscribe for one new share in XVIVO for a subscription price corresponding to 150 percent of the volume weighted average price for XVIVO´s shares quoted on Nasdaq Stockholm for each trading day during (i) the

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January - September 2019. The presentation will be held in English.Time: Thursday, October 24, 2019 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:https://event.on24.com/wcc/r/2099777/BE7D608FBDE20DDC5E0315BE8A97C986 or shortly before time of the conference starts on:Sweden dial in number: +46 (0) 8 5664 2651 USA dial in number: +1 631 913 1422 International dial in number: +44 (0) 3333 000 804Conference name: XVIVO Perfusion,

Nomination Committee of XVIVO Perfusion AB (publ)

The following members have been appointed to XVIVO Perfusion’s Nomination Committee for the 2020 Annual General Meeting: Henrik Blomquist, representing Bure Equity ABJoachim Spetz, representing Swedbank RoburMartin Lewin, representing Eccenovo ABGösta Johannesson, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company Nomination Committee which were determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on April 27, 2018. The members of the Nomination Committee together

XVIVO and MyCartis engage to develop a fast diagnostic test to assess the quality of donated organs before transplantation

Today, MyCartis and XVIVO Perfusion AB announce a collaboration to engage in the development of a fast diagnostic tool to timely assess the quality of donated organs during ex-vivo perfusion. Such test can guide the transplant surgeon and team on the quality of an organ and the chances of a positive outcome for the recipient.Despite yearly growing transplantation numbers, organ waiting lists continue to grow. The organ shortage represents a huge burden for the patient, for his or her direct environment, for the healthcare system and for the overall community. Ex vivo evaluation of solid

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January - June 2019. The presentation will be held in English.Time: Friday, July 12, 2019 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:http://event.on24.com/wcc/r/2032218-1/6B026E6E35CA4FDF60624857784BF612 or shortly before time of the conference starts on:Sweden dial in number: +46 (0) 8 5664 2651USA dial in number: +1 631 913 1422International dial in number: +44 (0) 3333 000 804 Conference name: XVIVO Perfusion, conference

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January - March 2019. The presentation will be held in English.Time: Wednesday, April 24, 2019 at 2.00 p.m. CET  Information regarding the conference can be found under the following link:https://financialhearings.com/event/11911 Phone numbers to the conference:Sweden dial in number: +46 (0)8 5055 8356 USA dial in number: +1 833 823 0590International dial in number: +44 (0) 3333 009 031 Participants from XVIVO Perfusion:Magnus Nilsson, CEOChristoffer Rosenblad, CFO

Conference call on Report on Operations

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the report on operations 2018. The presentation will be held in English.Time: Friday, February 8, 2019 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:http://event.on24.com/wcc/r/1917219-1/21654CA53CB3F837D9345305DFD1DAE7?partnerref=rss-events or shortly before time of the conference starts on:Sweden dial in number: +46 (0)8 5664 2651USA dial in number: +1 631 913 1422International dial in number: +44 (0) 3333 000 804Conference name: XVIVO Perfusion,

XVIVO Perfusion AB (publ) Interim Report January – September 2018

GOOD SALES GROWTH DRIVEN BY WARM PERFUSIONTHIRD QUARTER 2018 (JUL - SEP) • Total net sales in the quarter amounted to SEK 40.9 (32.3) million, corresponding to an increase of 27 percent. The increase corresponds to 18 percent in local currency. Net sales of non-durable goods in the quarter amounted to SEK 40.3 (31.6) million, corresponding to an increase of 27 percent in SEK. Sales of non-durable goods increased by 18 percent in local currency.• Sales from warm perfusion* showed a growth record of more than 60 percent during the quarter. Sales from warm perfusion represented 40 percent

Nomination Committee of XVIVO Perfusion AB (publ)

The following members have been appointed to XVIVO Perfusion’s Nomination Committee for the 2019 Annual General Meeting: Henrik Blomquist, representing Bure Equity ABJoachim Spetz, representing Swedbank RoburMartin Lewin, representing Eccenovo ABGösta Johannesson, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company Nomination Committee which were determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on April 27, 2018. The members of the Nomination Committee together

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the Interim report April - June 2018. The presentation will be held in English.Time: Friday, July 20, 2018 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:http://event.onlineseminarsolutions.com/wcc/r/1789895-1/370D12262D8ADF763D4C323D0DAEA7FB or shortly before time of the conference starts on:Sweden dial in number: +46 (0)8 5059 6306 USA dial in number: +1 718 873 9077International dial in number: +44 (0)203 139 4830Conference name: XVIVO Interim

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the Interim report January – March 2018. The presentation will be held in English.Time: Thursday, April 26, 2018 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:http://event.onlineseminarsolutions.com/wcc/r/1652265-1/E5006528AA7A332DBBA812E3AC538CFF?partnerref=rss-events or shortly before time of the conference starts on:Sweden dial in number: +46 (0)8 5059 6306 USA dial in number: +1 718 873 9077International dial in number: +44 (0)203 139 4830

XVIVO Perfusion AB (publ) Report on Operations 2017

CONTINUED GOOD GROWTH AND EBITDAFOURTH QUARTER 2017 (OCT - DEC) • Net sales of non-durable goods in the quarter amounted to SEK 39.4 (34.6) million, corresponding to an increase of 14 percent in SEK. Sales of non-durable goods increased by 21 percent in local currency. Net sales in the quarter amounted to SEK 41.6 (38.4) million, corresponding to an increase of 8 percent. The increase corresponds to 14 percent in local currency.• Operating income before depreciation and amortization (EBITDA), excluding items affecting comparability, amounted to SEK 9.1 (6.7) million, corresponding to

XVIVO Perfusion (publ) Interim Report January – September 2017

CONTINUED GROWTH AND PROGRESS IN THREE DEVELOPMENT PROJECTSTHIRD QUARTER 2017 (JUL - SEP) · Net sales of non-durable goods in the quarter amounted to SEK 31.6 (29.1) million, corresponding to an increase of 8 percent in SEK. Sales of non-durable goods increased by 11 percent in local currency. Net sales in the quarter amounted to SEK 32.3 (31.7) million, corresponding to an increase of 2 percent. The increase corresponds to 4 percent in local currency.   · Operating income before depreciation and amortization (EBITDA), excluding items affecting comparability, amounted to SEK 4.4 (5.

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report April – June 2017. The presentation will be held in English.Time: Friday, July 14, 2017 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:http://event.onlineseminarsolutions.com/wcc/r/1462726-1/EB0AE1BF526583E060C5E1E7F45EF62A?partnerref=rss-events or shortly before time of the conference starts on:Sweden dial in number: +46 (0)8 5059 6306USA dial in number: +1 718 873 9077International dial in number: +44 (0)203 139 4830Conference

The board of directors of XVIVO Perfusion resolves upon an up to approx. SEK 181 million share issue directed to institutional investors

The share issue directed to institutional investors and is subject to approval from an extraordinary general meetingNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONG KONG SWITZERLAND, SINGAPORE OR NEW ZEELAND OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL  The board of directors of XVIVO Perfusion AB (publ) (“XVIVO Perfusion” or the “Company”) has, in accordance with what the Company indicated in a press release on 16 March 2017, resolved, with

XVIVO Perfusion intends to undertake a private placement of shares

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONG KONG SWITZERLAND, SINGAPORE OR NEW ZEELAND OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL  XVIVO Perfusion AB (publ) (“XVIVO Perfusion” or the “Company”) announces its intention to undertake a private placement of shares. XVIVO Perfusion intends to offer up to 2,361,408 new shares in a private placement (the “Private Placement”). The possible Private Placement is directed to institutional Swedish

XVIVO Perfusion Interim report January – June 2016

ACQUISITION OF VIVOLINE STRENGTHENS XVIVO’S PRODUCT AND R&D PORTFOLIOSECOND QUARTER 2016 (APR – JUN) • Net sales in the quarter amounted to SEK 34.5 (29.1) million, corresponding to an increase of 18 percent. Net sales of non-Durable goods* in the quarter amounted to SEK 29.8 (27.4) million, corresponding to an increase of 9 percent in SEK and 11 percent in local currency.• Operating income before depreciation and amortization (EBITDA) excluding one-time expenses increased by 51 percent and amounted to SEK 6.9 (4.6) million, corresponding to an EBITDA margin of 20 percent. One-time

First Liver transplant with STEEN Solution™ performed

The first clinical liver transplant with a liver perfused with STEEN Solution™ was performed in Toronto, Canada. In total three successful liver transplants have been performed  as part of a phase 1 clinical trial at Toronto General Hospital (TGH)/University Health Network.In total three successful liver transplants were performed during the summer in Toronto, Canada. The liver was perfused with STEEN Solution™ under normothermic conditions. STEEN Solution™ was originally developed for warm perfusion and evaluation of lungs and is modified when perfusing a liver. The modified STEEN

There are no items matching the current filter
There are no more items matching the current filter
Back to top